JPRN-UMIN000043563尚未招募未知
Efficacy of isCGM on HbA1c improvement and behavior in Japanese type 2 diabetic patient - multicenter randomized prospective study - - HANABI STUDY
Tokyo Teishin Hospital0 个研究点目标入组 300 人开始时间: 2021年3月10日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Contraindication of Freestyle Libre on the attachment document 2)Patients with an HbA1c level of less than 7.0% (20 to 65 years old) and patients with an HbA1c level of less than 7.5% (65 to 75 years old) 3)Mentally handicapped patient unsuitable for study evaluation 4)Pregnant women 5)Poor prognostic patient with malignancy 6)Patient with progressive diabetic retinopathy 7)Less than eGFR 30 ml/min/1.73m2 8)Hemoglobinopathy 9)Exercise restricted patient 10)Patient in treatment with drugs affect blood glucose levels including steroids, anti-cancer drugs, interferon et al 11)Dementia 12)Patients with therapeutic contraindications to the use of Freestyle Libre 13)Patients deemed unsuitable for this study by the researcher in this study
研究者
相似试验
终止
不适用
The isCGM Use and Hypoglycemic Episodes and Fear of Hypoglycemia in Newly Diagnosed Type 1 DiabetesDiabetes Mellitus, Type 1NCT06414824Jagiellonian University28
已完成
4 期
SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLDNon-alcoholic Fatty Liver DiseaseNCT02649465Kanazawa University40
已完成
不适用
Insulin Pump vs Multiple Daily Injection on Cardiovascular Outcomes (ITALICO)Diabetes MellitusNCT03338439University of Pavia215
Unknown
不适用
Efficacy of hemoglobin A1C (HbA1C) achievement between insulin based therapy and dual oral hypoglycemic agents in newly diagnosed type 2 diabetes patients with very high hemoglobin A1Cnewly diagnosed type 2 diabetes patientshemoglobin A1C insulin based therapy dual oral hypoglycemic diabetes patientsTCTR20220210005ampang hospital76
终止
4 期
Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary CareDiabetes Mellitus, Type 2NCT00950534Sanofi25